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Abstract
Background: Clozapine is the only medication licensed for the treatment of resistant schizophrenia in the UK.
Although efficacious, a common and unpopular side effect of clozapine treatment is clozapine-induced
hypersalivation (CIH), which can contribute to non-adherence. The standard treatment for CIH in the UK is hyoscine
hydrobromide but this may aggravate cognitive deficits in patients with schizophrenia while glycopyrrolate may be
an effective alternative with a more tolerable side effect profile. There is currently no convincing evidence for
hyoscine, or any other medication, as an effective treatment for CIH.
Methods/design: This is a multicentre randomised, double-blind, placebo-controlled feasibility study of
glycopyrronium bromide (glycopyrrolate) and hyoscine hydrobromide (hyoscine) in patients with clozapine-induced
hypersalivation. We aim to recruit 42 patients who have been prescribed clozapine and are experiencing
hypersalivation, and randomise them to one of three study arms (either hyoscine, glycopyrrolate or placebo). The
primary outcome measures will be the participant recruitment and attrition rates, and the secondary outcome will
be the metrics of the daytime hypersalivation measure. After a 1-week washout period (discontinuing CIH
medication, if any), there will be a 4-week treatment period where participants will be titrated up to the maximum
tolerated dose of hyoscine, glycopyrrolate or placebo. Measurements of daytime salivation, nocturnal salivation,
cognition and side effects will be taken during home visits in week 2 and week 5. Information on salivation and
side effects will also be taken through telephone calls in week 3 and week 4. To gather information on the
experience of study participants, exit interviews will also be requested with all participants who drop out of the
study and a sample of participants who complete the study.
Discussion: There is currently no convincing evidence for hyoscine, or any other medication, as an effective
treatment for CIH. There is promising evidence that glycopyrrolate may be more successful in the treatment of CIH
causing fewer cognitive side effects. We propose to conduct a randomised placebo-controlled feasibility study of
glycopyrrolate and hyoscine in the treatment of clozapine-induced hypersalivation to inform the design of a future
efficacy trial.
Trial registration: Clinicaltrials.gov NCT02613494, 23 November 2015.
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Background
Study rationale
Clozapine is the only medication licensed for the treat-
ment of resistant schizophrenia in the UK. Approxi-
mately 20,000 patients are prescribed clozapine in the
UK and, in almost all cases, it is a lifelong prescription.
Clozapine-induced hypersalivation (CIH) is a common
side effect of clozapine treatment and occurs in up to
80% of patients [1, 2]. CIH may be the source of pro-
found embarrassment and social stigma, lowering self-
esteem, increasing social isolation and ultimately exacer-
bating psychological problems. CIH may also cause in-
flammation of the salivary glands, salivary calculi, and
skin infections [2, 3]. Sleep quality may also be adversely
affected, with some patients describing the sensation of
choking on excessive saliva at night [4]. There are ac-
companying practical and financial difficulties (e.g. the
regular disposal of soaked pillows and clothing) and a
recent survey of clozapine patients showed that hyper-
salivation is the most undesirable side effect of clozapine
treatment [5]. Crucially, adverse side effects may eventu-
ally lead to patients discontinuing clozapine treatment
[6], considerably increasing the risk of relapse and hospi-
talisation. The effective treatment of CIH is therefore
vital to patient experience and continued wellbeing.
Current treatment and limitations
Because CIH is not dose-related, a reduction in clozapine
dose is not an effective solution and non-pharmacological
interventions such as sugarless gum also have very little
effect [7]. As a result, CIH is invariably treated with medi-
cation. In the UK, the most commonly used medication
for CIH is hyoscine hydrobromide (‘hyoscine’), an anti-
muscarinic licensed as a prophylactic for motion sickness
and as a pre-operative drug to dry secretions. It is readily
absorbed from the gastrointestinal tract with an effective
bioavailability, for motion sickness, achieved 30 minutes
after oral administration. Hyoscine can cause a wide range
of side effects, most commonly drowsiness, dizziness and
constipation (which can be a lethal side effect of clozapine
treatment). In addition, hyoscine crosses the blood-brain
barrier, so may cause or exacerbate cognitive deficits, in-
cluding impairments of visual and verbal memory [8].
This is clinically significant, as cognitive deficits in schizo-
phrenia are common and associated with poor long-term
outcomes.
Literature reviews have noted that the majority of
studies in CIH provide no convincing evidence for any
drug, including hyoscine, as an effective treatment [9]. A
Cochrane review of the evidence base for the efficacy of
pharmacological treatments for CIH identified 15 rando-
mised controlled trials (RCTs) in the literature, with 14
of these studies conducted in China, significantly limit-
ing their generalizability [10]. The reviewers noted a
number of significant problems with study design and
data reporting, including the use of cross-over study de-
signs so treatment carry-over effects could not be ex-
cluded; the use of unvalidated rating scales to measure
hypersalivation; few reports of adverse effects; no reports
on effects on general functioning or quality of life; poor
quality of data reporting; and none of the studies included
hyoscine. The Cochrane review concluded, ‘there are cur-
rently insufficient data to confidently inform clinical prac-
tice, limitations of these studies are plentiful and the risk
of bias high’ and ‘it seems reasonable to study safe inter-
ventions for which there is a rationale’ [10].
Alternative treatment candidate
There is emerging evidence for glycopyrronium bromide
(‘glycopyrrolate’), for the treatment of CIH that may be
more efficacious, more tolerable and may cause less cog-
nitive impairment. Glycopyrrolate is an anti-muscarinic
with weak blood-brain-barrier penetration [11] and is
used widely in the UK as a pre-anaesthetic agent because
of its ability to decrease salivary production and gastric
acid. It is commonly prescribed by paediatricians in the
treatment of drooling in children with neurodevelop-
mental disorders [12]. It is reported to be well tolerated
and weak penetration of the blood-brain barrier suggests
that side effects involving cognitive impairment are less
likely to emerge. In trials of children and young people
with a neurological condition the dosage of glycopyrro-
late is titrated and dependent on weight, up to a max-
imum of 3 mg per dose given three times daily. In the
only RCT of glycopyrrolate for CIH glycopyrrolate was
dosed at 1 mg twice daily. After oral ingestion peak ef-
fect is seen at approximately 60 minutes post ingestion.
Three placebo-controlled RCTs of glycopyrrolate (two
in children with neurological disorders, one in adults
with Parkinson’s disease) have shown significant reduc-
tions in excess salivation as a result of glycopyrrolate
treatment [13–15]. However the aetiology of drooling in
children is likely to be different from drug-induced hy-
persalivation. Oral preparations of glycopyrrolate are not
licensed in the UK for the treatment of CIH, but case re-
ports have described the efficacy of glycopyrrolate in the
treatment of CIH [16] and a small (n = 13) double-blind,
randomised crossover study of glycopyrrolate and biperi-
den (a centrally acting anticholinergic similar to hyos-
cine) in CIH reported a significantly greater reduction in
hypersalivation scores in patients receiving glycopyrro-
late than those receiving biperiden [17]. Furthermore,
participants receiving biperiden showed significantly re-
duced cognitive functioning in comparison to those re-
ceiving glycopyrrolate. The side effects of glycopyrrolate
include dry mouth, vomiting, constipation, urinary re-
tention, transient bradycardia, photophobia, flushing of
skin and nasal congestion [18]. In one paediatric study,
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20% of children who had been administered glycopyrro-
late withdrew from the study owing to adverse side ef-
fects [13]. However, in the psychiatric population it
appears to be well tolerated [17].
The present study
Several parameters require clarification before a full
efficacy trial may proceed. First, whether patients cur-
rently undergoing clozapine treatment would be will-
ing to join a randomised placebo-controlled trial
(RCT) of hypersalivation medications, and if they are
willing to be recruited, whether they will remain in
the trial. A secondary issue is there is very little data
on the parameters of the daytime hypersalivation
measure, the Drooling Rating Scale (DRS), and pre-
liminary work is needed to determine the standard
deviation of this measure to inform a sample size cal-
culation for a future RCT.
Summary
CIH is a common and profoundly debilitating side ef-
fect of clozapine treatment that may contribute to
non-adherence to treatment [6]. Owing to a poor evi-
dence base and the absence of a viable alternative, cli-
nicians prescribe hyoscine, which may cause
impairments in cognition, which in turn may worsen
short- and long-term clinical outcomes. There is
promising evidence that glycopyrrolate may be more
successful in the treatment of CIH causing fewer cog-
nitive side effects. There is a strong rationale for de-
veloping a study to compare these medications
against each other and we propose to conduct a ran-
domised placebo-controlled feasibility study of glyco-
pyrrolate and hyoscine in the treatment of clozapine-
induced hypersalivation to inform the design of a fu-
ture efficacy trial.
Methods and design
Primary objective
To assess the feasibility of recruiting community patients
from different centres, the feasibility study will:
 Ascertain whether the study design is acceptable to
participants, including randomisation and use of
telephone interviews.
 Ascertain whether the interventions are acceptable
to participants and indicate likely attrition rates and
tolerability.
The primary outcome measures will be participant re-
cruitment and attrition rates.
Secondary objective
Ascertain the standard deviation of the daytime hyper-
salivation measure to estimate the required sample size
for a future efficacy RCT.
Study design
This is a multicentre randomised, double-blind, placebo-
controlled feasibility study of glycopyrrolate and hyos-
cine in patients with clozapine-induced hypersalivation.
We will recruit 42 patients who have been prescribed
clozapine and are experiencing hypersalivation.
Eligible participants will be recruited to a 5-week study
consisting of a 1-week washout period followed by a 4-
week treatment period. Participants will be randomised
on a 1:1:1 basis to one of three study arms (hyoscine,
glycopyrrolate or placebo). Self-report measures of sali-
vation and side effects will be taken weekly and cogni-
tion will be assessed at the beginning and end of the
study. See Fig. 1 for an overview of the study and Add-
itional file 1 for the Standard Protocol Items: Recom-
mendations for Interventional Trials (SPIRIT) checklist.
Participant population
Participants will be capacitous, consenting in-patients
and community patients recruited from Mersey Care
NHS Trust (MCT) and Lancashire Care NHS Founda-
tion Trust (LCFT).
Inclusion criteria
A participant will qualify for inclusion if he/she:
 has been prescribed clozapine for a minimum of
3 months.
 is experiencing hypersalivation (minimum score of 4
on the Drooling Rating Scale).
 is aged between 18 and 65 years and English
speaking.
 is capable of understanding the information given
and can provide informed consent prior to study
specific procedures.
Exclusion criteria
 Medical conditions that could influence
hypersalivation (e.g. idiopathic Parkinson’s disease).
 Neurological conditions that could affect cognitive
functioning during the course of the study (e.g.
unstable epilepsy).
 History of an allergic reaction to hyoscine
hydrobromide or glycopyrrolate.
 Any of the following contraindications to hyoscine
or glycopyrrolate as stated in the British National
Formulary: prostatic enlargement, myasthenia gravis,
pyloric stenosis, paralytic ileus, toxic megacolon.
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 Any of the following cautions to hyoscine or
glycopyrrolate as stated in the British National
Formulary e.g. closed angle glaucoma, chronic heart
failure, chronic lung disease, untreated stomach
ulcer, ulcerative colitis, significant liver problems,
significant kidney disease, Down’s syndrome,
persistent untreated tachycardia, overactive thyroid
gland.
Fig. 1 Study flow chart for GOTHIC1
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 Current prescription for potassium chloride,
digoxin, cimetidine, indacaterol, amantadine,
atenolol, levodopa or medications that, in the view
of the trial pharmacist, have a significant
anticholinergic profile.
 A woman of childbearing potential who has tested
negative for pregnancy, unable or unwilling to use
contraception during the study.
 Participation in another therapeutic study within the
preceding 12 weeks or use of other investigational
drugs or agents.
 Active suicidal ideation.
 Inpatient on a mental health ward.
Identification, recruitment and consenting of participants
Participants will be recruited from outpatient cloza-
pine clinics from two NHS mental health trusts. R&D
approval will be obtained from each mental health
trust prior to start of the study. The study protocol
and information sheets will be provided to clinical
staff at each participating site who will be asked to
identify potential participants who fulfil inclusion/ex-
clusion criteria. Clinical staff will approach potential
patients and seek their agreement for research staff to
approach them about participation in the study.
After permission has been obtained to approach a
potential participant, a researcher will write to them
to send study information. The researcher will sub-
sequently contact the patient by telephone and en-
quire if they are interested in participation. If the
patient provisionally agrees, an appointment will be
made for the researcher to visit the participant (ei-
ther at the participant’s home or at their next clinic
appointment), in order to answer any further ques-
tions the participant may have and to obtain written
informed consent.
Following recruitment and consent, the Responsible
Clinician and the participant’s GP will be informed in
writing. The original, signed copy of the consent form
will be retained in the Investigator site file with a
copy in clinical notes and a copy provided to the par-
ticipant. If new safety information results in signifi-
cant changes in the risk/benefit assessment, the
Participant Information Sheet and associated consent
form will be reviewed and updated if necessary. If the
Participant Information Sheet and consent form are
updated, all participants (including those already re-
cruited), will be informed of the new information,
given a copy of the revised documents and asked to
re-consent to continue in the trial. A screening log
will be maintained for all individuals that are offered
trial participation and reasons for non-recruitment
and screen failures will be recorded.
Randomisation and blinding
Randomisation will be coordinated by the Manchester
Academic Health Sciences Centre Trials Coordination
Unit (MAHSC-CTU). After participants have given writ-
ten consent to participation, a researcher will contact
MAHSC-CTU for allocation to one of the three arms of
the study on a 1:1:1 basis. The three arms are:
 Hyoscine (arm A – treatment)
 Glycopyrrolate (arm B – treatment)
 Placebo (arm C – control)
Neither the participant nor the researchers will be aware
of the arm to which each participant has been allocated
and details of the allocation will remain concealed from the
research team until after data lock. Blinding of participants
and the research team to allocation status will be assured
by identical capsule appearance and identical labelling on
trial medication (apart from labels identifying the patient).
Label randomisation was achieved by a computer-
generated list compiled by a statistician at MAHSC-CTU
for 42 allocations in two blocks of 21 and supplied to the
pharmaceutical company responsible for packaging and la-
belling of the bottles. In the event a patient develops any
side effects where drug unblinding is required, the treating
physician will be made aware of the study drug, possible
side effects and make the appropriate decision whether to
continue or discontinue the drug. The safety and wellbeing
of the patient will be paramount at all times.
Participant withdrawal and replacement
Participants who are removed from the study due to ad-
verse events will be treated and followed according to
accepted medical practice. The research team may with-
draw a participant from trial because of:
 Adverse event or serious adverse event
 Withdrawal of consent
 Persistent non-compliance with the study protocol
 Sponsor’s decision to terminate the study
 Withdrawal by the Investigator for clinical reasons
not related to the study drugs
 Pregnancy
 Symptomatic deterioration including patients who
experience rapid deterioration before completion of
the protocol treatment.
If a patient withdraws or is withdrawn from the study,
it is not the intention to replace them.
Study drug dosage
Hyoscine
The dosing schedule for hyoscine hydrobromide during
the 5-week study period is: week 1 - washout period
Qurashi et al. Trials  (2016) 17:553 Page 5 of 9
(discontinue existing medication for CIH, if any); week 2
- 300 micrograms twice daily; weeks 3, 4 and 5 - 300 mi-
crograms three times daily. This is within the dose range
recommended in the British National Formulary (BNF)
(off-licence use for hypersalivation), the Maudsley pre-
scribing guidelines [19] for the treatment of CIH and is
consistent with current prescribing practice.
Glycopyrrolate
The dosing schedule for glycopyrronium bromide during
the 5-week study period will be: week 1 - washout
period (discontinue existing medication for CIH, if any);
week 2 - 1 milligram twice daily; weeks 3, 4 and 5 - 1
milligram three times daily.
Drug administration and accountability
Study drugs and placebo will be dispensed from the trial
pharmacy and delivered to participants by the research
team. The trial pharmacy will carry out study drug dis-
pensing procedures according to relevant standards,
local guidelines and in accordance with Good Clinical
Practice guidelines. Participants may receive concomi-
tant therapy deemed to provide adequate care at the
treating clinicians’ discretion. The correspondence to the
treating mental health clinician and general practitioner
following participant recruitment will advise that the
study pharmacist is contacted if concomitant medication
is prescribed to avoid the prescription of drugs with a
significant anticholinergic profile.
The use of experimental drugs is not permitted until
at least 14 days after the completion of the study. All
medications or other treatments taken by the participant
during the study (including those initiated prior to the
start of the study) must be recorded in the patient’s clin-
ical notes.
Drug compliance and management
Administration of hyoscine, glycopyrrolate or placebo
will be recorded in the Case Report Form (CRF). At each
weekly contact by the researcher, the participant will be
asked about how many doses were taken or omitted.
Omission of drug doses will be recorded in the CRF.
Participants will remain under the care of their clin-
ical team during the period of the study. In the event
of an accidental or intentional overdose participants
will be advised to seek urgent medical attention in
casualty departments and emergency unblinding will
be undertaken.
Study procedures
Data collection procedures
There will be three visits in total by a researcher and
there may also be one further visit to conduct an exit
interview if a participant consents to this. A baseline
visit will take place at the end of the week 1 washout
period, where a researcher will visit the participant at
home to deliver trial medication for week 2 and admin-
ister all assessment measures. The maintenance visit will
take place at the end of week 2, where a researcher will
visit the participant at home to deliver trial medication
for weeks 3–5 and administer hypersalivation scales and
the side effects scale. The final visit will take place at the
end of week 5 where a researcher will visit the partici-
pant at home to administer all assessment measures
again. Appointments will be made on each occasion and
researchers will remind participants of forthcoming ap-
pointments via telephone call. If a participant is not
available when the researcher arrives for any visit, an-
other appointment will be made as soon as possible.
An important aim is to explore the feasibility of col-
lecting information on hypersalivation and side effects
using weekly telephone calls assessing. At the end of
week 3 and week 4, a researcher will telephone the par-
ticipant at a prearranged time and administer hypersali-
vation scales and the side effects scale.
Researchers will request an exit interview with all
participants who drop out of the study and a number
of participants who complete the study until 12 inter-
views have been conducted. Interviews will take place
at the participant’s home at their convenience Two
researchers (one of whom will also be a service user)
will conduct a 20-minute interview to explore the
participant’s experience of taking part in the study,
exploring the acceptability of the study methods and
seeking advice on how study participation experience
could be improved. Of particular interest will be the
views of participants who did not complete the study
and in particular their reasons for dropping out, so
that this may inform the design of the future RCT
with respect to reducing attrition rates.
A review of each participant’s case notes will be under-
taken on three occasions (consent, baseline and final
visit) to obtain information on concurrent medication
prescribed and record any adverse or side effects not dir-
ectly reported by the participant.
Assessment measures
Drooling Rating Scale (DRS) The DRS [20] is a two-
item scale comprising drooling severity and frequency
assessments that combine to form a score ranging from
2 to 9. Whilst it has not been validated and its metrics
(standard deviation, mean, sensitivity to change) are un-
known in a UK CIH population, it has good face validity
and has been used in published research on paediatric
hypersalivation [17, 21]. A feasibility aim is to establish
its metrics in a UK CIH population.
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Nocturnal Hypersalivation Rating Scale (NHRS) The
NHRS [22] is a validated single-item 5-point self-report
scale for measuring the degree of nocturnal salivation
that a respondent experiences. The NHRS is the only
scale specifically mentioned in the Cochrane review for
treatments for CIH [10] that is recommended for inclu-
sion in future studies of the efficacy of CIH
interventions.
Brief Assessment of Cognition in Schizophrenia
(BACS) The BACS [23] comprises a short battery of
tests devised for easy administration and scoring which
assess the extent of cognitive impairment in schizophre-
nia. The battery includes brief assessments of executive
functions, verbal fluency, attention, verbal memory,
working memory and motor speed and requires approxi-
mately 30 minutes to complete.
Liverpool University Neuroleptic Side Effect Rating
Scale (LUNSERS) LUNSERS [24] is a 51-item checklist
of side effects which assesses on a 5-point scale the de-
gree to which respondents have experienced that side ef-
fect in the last month. It shows good reliability and
validity, correlating well with other clinician-
administered side effect scales. A modified LUNSERS
will be used to assess side effects in the previous week
(rather than month).
Sample size considerations
Our intended sample size is based on recruiting suffi-
cient numbers to fulfil the feasibility aims of the study.
The intention is to recruit 14 patients to each of three
study arms because recruitment for a total sample of 42
will allow a good estimate of recruitment and attrition
rates and allows a conservative estimated recruitment
rate of one participant per week over an 11-month
period. We estimate an attrition rate of 20% (which is
substantially higher than in previous studies) which im-
plies nine dropouts and this allows clear differentiation
from one criterion (40% drop-out, n = 17) for future pro-
gression to a full efficacy trial, with more than 80%
power to detect a difference of this size with alpha at
0.25 (one-tailed). This is consistent with the relaxed
power and alpha criteria suitable for an early phase
study of this type [25, 26] specifically the alpha 0.25 cri-
terion advocated by Schoenfeld [27]. As a secondary
consideration, this sample size also gives more than 80%
power to detect a difference between arms of effect size
0.5 [17] with alpha 0.1 (two-tailed), assuming correlation
between measures at each of five time points of r > =
0.5. Furthermore, 14 in each arm will be sufficient to
gain an indication of the metrics (standard deviation
(SD), mean, sensitivity to change) for the putative pri-
mary outcome measure (DRS) in placebo and active
treatment arms recruited from this population for a fu-
ture efficacy study.
Safety reporting procedures
All adverse events (AEs) suspected of having a causal re-
lationship to either study drug will be captured in the
participant’s clinical notes and CRF from the start of
treatment (week 2) until the end of the participant’s in-
volvement in the study. Serious adverse events (SAEs)
will also be reported to the MAHSC-CTU within
24 hours of observing or learning about the event. The
study manager will liaise with the Chief Investigator (CI)
to evaluate the event for seriousness, causality and ex-
pectedness. All SAEs will be followed up until resolution
and the participating site must provide follow-up reports
if the SAE has not resolved at the time the initial report
was submitted.
Trial management and quality assurance
The study is managed through the Trial Management
Group (TMG) which includes those individuals respon-
sible for the day-to-day management of the study includ-
ing the CI, co-investigators and the study manager. The
TMG has operational responsibility for the conduct of
the study including monitoring overall progress and tak-
ing appropriate action to safeguard participants and the
quality of the study. The TMG meets at least quarterly
once the study is actively recruiting. The study manager
and CI will ensure that all relevant issues and actions
discussed during the meeting are followed up and re-
solved. At least annually, the TMG will be extended to
invite an independent chair (not involved directly in the
study) and additional independent members, a service
user representative, and the assembly will be conducted
as a Trial Steering Committee (TSC) meeting. The TSC
takes responsibility for the scientific integrity of the
study, the scientific validity of the study protocol, assess-
ment of the study quality and conduct as well as for the
scientific quality of the final study report. Decisions
about the continuation or termination of the study or
substantial amendments to the protocol are the respon-
sibility of the TSC. The Principal Investigators at the
participating sites are responsible for the day-to-day run-
ning of the study at their site.
TSC meetings will be organised by the CI via the study
manager. Minutes will be taken at TSC meetings and
copies of the minutes will be filed in the Trial Master
File. The study manager and CI will ensure that all rele-
vant issues and actions discussed during the meeting are
followed up and resolved. The committee’s terms of ref-
erence, roles and responsibilities will be defined in a
charter issued by the MAHSC-CTU.
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No Data Monitoring Committee will be required for
this study because the outcome measures do not require
the review of study data.
Discussion
We aim to conduct a large-scale randomised placebo-
controlled trial of hyoscine and glycopyrrolate in the treat-
ment of clozapine-induced hypersalivation. As a step to-
wards this, the present feasibility study will provide
information on recruitment, tolerability and attrition, ac-
ceptability of the study design and the views of study partic-
ipants who complete and drop out of the study to inform
both the viability and design of the future efficacy trial.
Trial sponsor
The Sponsor of the study is Mersey Care NHS Founda-
tion Trust. The Sponsor has no part in study design, nor
the collection, management and analysis of data, nor the
decisions to submit reports for publication.
Trial status
This clinical trial was registered on 23 November 2015
(ClinicalTrials.gov identifier: NCT02613494) and will
begin recruitment in January 2017. The estimated study
completion date is September 2017.
Additional file
Additional file 1: Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) checklist. (DOC 120 kb)
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